ArticleAntimicrobial agents and chemotherapy2017
Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae.
Open access · bronzeAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Pooled it
- Exploring heterogeneity in antibiotic choices for bloodstream infections caused by AmpC-producing enterobacterales: results from a case-vignette study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Article
- Characteristics and Outcomes of Patients Treated with Carbapenem Versus Non-carbapenem Therapy for AmpC-Producing Enterobacterales Bacteremia: A Retrospective Study.Infectious diseases and therapy · 2025Article
- Evolution of β-Lactam Antibiotic Resistance inMicroorganisms · 2025Review
- A streamlined method to determine the antibiotic resistance of plaque-forming predatory bacteria.Frontiers in microbiology · 2025Article
- Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales.Pharmacy (Basel, Switzerland) · 2024Review
- Clinical Outcomes of Patients with AmpC-Beta-Lactamase-Producing Enterobacterales Bacteremia Treated with Carbapenems versus Non-Carbapenem Regimens: A Single-Center Study.Antibiotics (Basel, Switzerland) · 2024Article
- A targeted likelihood estimation comparing cefepime and piperacillin/tazobactam in critically ill patients with community-acquired pneumonia (CAP).Scientific reports · 2024Article
- Burden and Management of Multi-Drug Resistant Organism Infections in Solid Organ Transplant Recipients Across the World: A Narrative Review.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Mortality and Risk Factors of Death in Patients with AmpCInfection and drug resistance · 2024Article
- Cefepime Versus Piperacillin-Tazobactam for the Treatment of Intra-Abdominal Infections Secondary to Potential AmpC Beta-Lactamase-Producing Organisms.Hospital pharmacy · 2023Article
- Bloodstream Infections by AmpC-Producing Enterobacterales: Risk Factors and Therapeutic Outcome.Pathogens (Basel, Switzerland) · 2023Article
- Carbapenem alternatives for treatment of bloodstream infections due to AmpC producing enterobacterales.Annals of clinical microbiology and antimicrobials · 2023Observational
- The Clinical Evaluation of Third-generation Cephalosporins As Definitive Therapy for Enterobacter spp. and Klebsiella aerogenes Bacteremia.Internal medicine (Tokyo, Japan) · 2023Observational
- The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock.Heliyon · 2023Article
- Antibiotic stewardship in the ICU: time to shift into overdrive.Annals of intensive care · 2023Review
- Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients.The Journal of antimicrobial chemotherapy · 2023Article
- β-Lactam Resistance in ESKAPE Pathogens Mediated Through Modifications in Penicillin-Binding Proteins: An Overview.Infectious diseases and therapy · 2023Review
- Evaluating the Use of Meropenem in Hematologic Patients with Febrile Neutropenia: A Retrospective Observational Single-Cohort Study.Mediterranean journal of hematology and infectious diseases · 2023Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 3 institutions in 1 country.
Lucy ChengDepartment of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA.
Brian C NelsonNewYork-Presbyterian Hospital, New York, New York, USA.
Monica MehtaNewYork-Presbyterian Hospital, New York, New York, USA.
Nikhil SevalDepartment of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA.
Sarah ParkDepartment of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA.
Marla J GiddinsDepartment of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA.
Qiuhu ShiNew York Medical College, Valhalla, New York, USA.
Susan WhittierDepartment of Pathology and Cell Biology, Clinical Microbiology Laboratory, Columbia University Medical Center, New York, New York, USA.
Angela Gomez-SimmondsDepartment of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA.
Anne-Catrin UhlemannDepartment of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA au2110@columbia.edu.
Columbia University Irving Medical Center · USNew York Hospital Queens · USNew York Medical College · US
Funding
Carbapenem-resistant bacterial colonization and infection after liver transplantR01AI116939 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI UHLEMANN, ANNE-CATRIN · 2015 to 2019
$2.4MNIAID NIH HHS R01 AI116939
Abstract
PubMed holds no abstract for this paper.
Indexed as
AgedAnti-Bacterial AgentsBacteremiaBacterial Proteinsbeta-LactamasesCase-Control StudiesEnterobacteriaceaeGenotypeHumansMaleMiddle AgedPenicillanic AcidPhenotypePiperacillinPiperacillin, Tazobactam Drug CombinationSerratia marcescensAmpC beta-lactamasesAnti-Bacterial AgentsBacterial Proteinsbeta-LactamasesPenicillanic AcidPiperacillinPiperacillin, Tazobactam Drug CombinationAmpC beta-lactamasesbacteremiapiperacillin-tazobactam
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.